PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
Antigens, Neoplasm
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Epithelial-Mesenchymal Transition
/ genetics
Female
Gene Expression Regulation, Neoplastic
Gene Silencing
Humans
Neoplasm Invasiveness
Phenotype
RNA, Messenger
/ genetics
Survival Analysis
Transcription Factors
/ metabolism
Triple Negative Breast Neoplasms
/ genetics
Epithelial-to-mesenchymal transition
Invasion
Migration
PRAME
PReferentially Antigen expressed in Melanoma
Triple negative breast cancer
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
03 01 2019
03 01 2019
Historique:
received:
19
09
2018
accepted:
21
12
2018
entrez:
4
1
2019
pubmed:
4
1
2019
medline:
9
4
2020
Statut:
epublish
Résumé
The triple negative breast cancer (TNBC) paradox marks a major challenge in the treatment-decision making process. TNBC patients generally respond better to neoadjuvant chemotherapy compared to other breast cancer patients; however, they have a substantial higher risk of disease recurrence. We evaluated the expression of the tumor-associated antigen PReferentially Antigen expressed in MElanoma (PRAME) as a prognostic biomarker in breast cancer and explored its role in cell migration and invasion, key hallmarks of progressive and metastatic disease. TCGA and GTeX datasets were interrogated to assess the expression of PRAME in relation to overall and disease-free survival. The role of PRAME in cell migration and invasion was investigated using gain- and loss-of-function TNBC cell line models. We show that PRAME promotes migration and invasion of TNBC cells through changes in expression of E-cadherin, N-cadherin, vimentin and ZEB1, core markers of an epithelial-to-mesenchymal transition. Mechanistic analysis of PRAME-overexpressing cells showed an upregulation of 11 genes (SNAI1, TCF4, TWIST1, FOXC2, IL1RN, MMP2, SOX10, WNT11, MMP3, PDGFRB, and JAG1) and downregulation of 2 genes (BMP7 and TSPAN13). Gene ontology analyses revealed enrichment of genes that are dysregulated in ovarian and esophageal cancer and are involved in transcription and apoptosis. In line with this, interrogation of TCGA and GTEx data demonstrated an increased PRAME expression in ovarian and esophageal tumor tissues in addition to breast tumors where it is associated with worse survival. Our findings indicate that PRAME plays a tumor-promoting role in triple negative breast cancer by increasing cancer cell motility through EMT-gene reprogramming. Therefore, PRAME could serve as a prognostic biomarker and/or therapeutic target in TNBC.
Sections du résumé
BACKGROUND
The triple negative breast cancer (TNBC) paradox marks a major challenge in the treatment-decision making process. TNBC patients generally respond better to neoadjuvant chemotherapy compared to other breast cancer patients; however, they have a substantial higher risk of disease recurrence. We evaluated the expression of the tumor-associated antigen PReferentially Antigen expressed in MElanoma (PRAME) as a prognostic biomarker in breast cancer and explored its role in cell migration and invasion, key hallmarks of progressive and metastatic disease.
METHODS
TCGA and GTeX datasets were interrogated to assess the expression of PRAME in relation to overall and disease-free survival. The role of PRAME in cell migration and invasion was investigated using gain- and loss-of-function TNBC cell line models.
RESULTS
We show that PRAME promotes migration and invasion of TNBC cells through changes in expression of E-cadherin, N-cadherin, vimentin and ZEB1, core markers of an epithelial-to-mesenchymal transition. Mechanistic analysis of PRAME-overexpressing cells showed an upregulation of 11 genes (SNAI1, TCF4, TWIST1, FOXC2, IL1RN, MMP2, SOX10, WNT11, MMP3, PDGFRB, and JAG1) and downregulation of 2 genes (BMP7 and TSPAN13). Gene ontology analyses revealed enrichment of genes that are dysregulated in ovarian and esophageal cancer and are involved in transcription and apoptosis. In line with this, interrogation of TCGA and GTEx data demonstrated an increased PRAME expression in ovarian and esophageal tumor tissues in addition to breast tumors where it is associated with worse survival.
CONCLUSIONS
Our findings indicate that PRAME plays a tumor-promoting role in triple negative breast cancer by increasing cancer cell motility through EMT-gene reprogramming. Therefore, PRAME could serve as a prognostic biomarker and/or therapeutic target in TNBC.
Identifiants
pubmed: 30602372
doi: 10.1186/s12967-018-1757-3
pii: 10.1186/s12967-018-1757-3
pmc: PMC6317205
doi:
Substances chimiques
Antigens, Neoplasm
0
PRAME protein, human
0
RNA, Messenger
0
Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Subventions
Organisme : Qatar Biomedical Research Institute, Qatar Foundation
ID : VR80
Pays : International
Organisme : Qatar Biomedical Research Institute, Qatar Foundation
ID : VR94
Pays : International
Références
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
PLoS One. 2016 Jul 08;11(7):e0149640
pubmed: 27391090
Transl Oncol. 2018 Apr;11(2):311-329
pubmed: 29413765
Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19204-9
pubmed: 22080605
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Mol Clin Oncol. 2014 Mar;2(2):245-251
pubmed: 24649341
Cold Spring Harb Perspect Biol. 2012 Feb 01;4(2):
pubmed: 22300978
Cell Physiol Biochem. 2015;37(4):1271-8
pubmed: 26431436
Gastrointest Tumors. 2017 Mar;3(3-4):128-135
pubmed: 28611979
Sci Rep. 2016 Feb 10;6:21520
pubmed: 26861754
Clin Cancer Res. 2016 Mar 1;22(5):1234-42
pubmed: 26933176
Leuk Res. 2012 Jul;36(7):895-9
pubmed: 22503131
Biomark Med. 2013 Aug;7(4):575-8
pubmed: 23905893
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10069-74
pubmed: 17537911
PLoS One. 2017 Jun 16;12(6):e0179501
pubmed: 28622390
Gynecol Oncol. 2003 Apr;89(1):77-83
pubmed: 12694657
Breast Cancer Res Treat. 2008 May;109(2):359-65
pubmed: 17624586
Leuk Res. 2011 Sep;35(9):1219-25
pubmed: 21550659
Tumour Biol. 2016 May;37(5):6349-58
pubmed: 26631031
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Cell. 2005 Sep 23;122(6):835-47
pubmed: 16179254
Cancer Lett. 1999 Aug 3;142(2):179-84
pubmed: 10463774
Cell Physiol Biochem. 2018;45(3):1121-1135
pubmed: 29439259
Ann Hematol. 2008 Oct;87(10):809-18
pubmed: 18587578
Cancer Res. 2007 Sep 15;67(18):8742-51
pubmed: 17875715
Curr Mol Med. 2013 Feb;13(2):296-304
pubmed: 23228130
Front Immunol. 2018 May 01;9:947
pubmed: 29770138
Br J Cancer. 2008 Aug 5;99(3):398-403
pubmed: 18648365
Clin Cancer Res. 2005 Jun 15;11(12):4357-64
pubmed: 15958618
Immunity. 1997 Feb;6(2):199-208
pubmed: 9047241
Genes Chromosomes Cancer. 2007 Sep;46(9):796-804
pubmed: 17534929
Int J Clin Exp Pathol. 2015 Aug 01;8(8):9522-32
pubmed: 26464715
J Cancer Res Clin Oncol. 2007 Oct;133(10):761-9
pubmed: 17486367
Cancer Res. 2005 Aug 15;65(16):7348-55
pubmed: 16103086
PLoS One. 2013;8(2):e55897
pubmed: 23409080
Cell Rep. 2015 Sep 29;12(12):2035-48
pubmed: 26365194
Hum Pathol. 2013 Jun;44(6):959-65
pubmed: 23260325
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Gene. 2016 Dec 5;594(1):160-164
pubmed: 27632898
Lung Cancer. 2016 Nov;101:137-144
pubmed: 27794402
Breast Cancer Res Treat. 2008 Oct;111(3):439-48
pubmed: 17990101
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Clin Lab. 2014;60(1):55-61
pubmed: 24600975
Cancer Res. 2006 Nov 15;66(22):10639-42
pubmed: 17108098
Blood. 2006 Dec 15;108(13):4109-17
pubmed: 16931630
Biochem Biophys Res Commun. 2012 Mar 23;419(4):801-8
pubmed: 22390931
Front Oncol. 2018 Jun 14;8:227
pubmed: 29963498
Cancer Lett. 2017 Sep 10;403:144-151
pubmed: 28634046
Clin Sarcoma Res. 2017 Jun 15;7:11
pubmed: 28630682
Mol Cancer. 2010 Aug 27;9:226
pubmed: 20799951
Oral Oncol. 2013 Feb;49(2):144-51
pubmed: 22944049
Front Oncol. 2014 Sep 25;4:254
pubmed: 25309874
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
Int J Cancer. 2013 Mar 1;132(5):1133-45
pubmed: 22752881
JAMA Ophthalmol. 2017 Jun 1;135(6):541-549
pubmed: 28448663